TransMedics Group’s (TMDX) Overweight Rating Reiterated at Piper Sandler

Piper Sandler restated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report released on Tuesday, Benzinga reports. They currently have a $180.00 target price on the stock.

TMDX has been the subject of several other research reports. Needham & Company LLC dropped their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird cut their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday. Canaccord Genuity Group decreased their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley upped their price target on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Stock Up 0.1 %

Shares of NASDAQ TMDX opened at $81.97 on Tuesday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.48 and a current ratio of 8.20. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $177.37. The stock’s 50-day simple moving average is $142.38 and its 200-day simple moving average is $139.36. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of 87.20 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, equities analysts anticipate that TransMedics Group will post 1.11 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares in the company, valued at approximately $1,353,514.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the transaction, the director now owns 732 shares in the company, valued at approximately $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock worth $9,518,181 over the last three months. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank raised its holdings in TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares during the period. Pitcairn Co. lifted its position in shares of TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after purchasing an additional 78 shares during the last quarter. Harbour Capital Advisors LLC boosted its stake in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares during the period. Signaturefd LLC grew its holdings in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the last quarter. Finally, Arizona State Retirement System increased its position in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after buying an additional 186 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.